Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Hall

Showing results (131-140 of 160) with videos related to

Pageof 16
Sort By:
Annals of the Rheumatic Diseases|June 10, 2015
Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)Gerd R Burmester, Andrea Rubbert-Roth, Alain Cantagrel, et al.
Annals of the Rheumatic Diseases|August 2, 2013
A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)Gerd R Burmester, Andrea Rubbert-Roth, Alain Cantagrel, et al.
Lancet (London, England)|November 20, 2016
Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE studyJosef S Smolen, Gerd-Rüdiger Burmester, Bernard Combe, et al.
The New England Journal of Medicine|June 19, 2014
Tofacitinib versus methotrexate in rheumatoid arthritisEun Bong Lee, Roy Fleischmann, Stephen Hall, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 9, 2019
A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial SpondyloarthritisAtul Deodhar, Lianne S Gensler, Jonathan Kay, et al.
Clinical and Vaccine Immunology : CVI|December 26, 2014
An inactivated Ross River virus vaccine is well tolerated and immunogenic in an adult population in a randomized phase 3 trialNina Wressnigg, Maikel V W van der Velden, Daniel Portsmouth, et al.
Vaccine|April 7, 2015
Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trialJosefina B Cadorna-Carlos, Terry Nolan, Charissa Fay Borja-Tabora, et al.
Annals of the Rheumatic Diseases|November 5, 2020
Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritisRoy M Fleischmann, Ricardo Blanco, Stephen Hall, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 10, 2020
Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo-Controlled Phase III StudyAtul Deodhar, Ricardo Blanco, Eva Dokoupilová, et al.
Annals of the Rheumatic Diseases|March 6, 2014
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitorArthur Kavanaugh, Philip J Mease, Juan J Gomez-Reino, et al.
Pageof 16

Showing results (131-140 of 160) with videos related to

Sort By:
Pageof 16
Annals of the Rheumatic Diseases|June 10, 2015
Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)Gerd R Burmester, Andrea Rubbert-Roth, Alain Cantagrel, et al.
Annals of the Rheumatic Diseases|August 2, 2013
A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)Gerd R Burmester, Andrea Rubbert-Roth, Alain Cantagrel, et al.
Lancet (London, England)|November 20, 2016
Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE studyJosef S Smolen, Gerd-Rüdiger Burmester, Bernard Combe, et al.
The New England Journal of Medicine|June 19, 2014
Tofacitinib versus methotrexate in rheumatoid arthritisEun Bong Lee, Roy Fleischmann, Stephen Hall, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 9, 2019
A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial SpondyloarthritisAtul Deodhar, Lianne S Gensler, Jonathan Kay, et al.
Clinical and Vaccine Immunology : CVI|December 26, 2014
An inactivated Ross River virus vaccine is well tolerated and immunogenic in an adult population in a randomized phase 3 trialNina Wressnigg, Maikel V W van der Velden, Daniel Portsmouth, et al.
Vaccine|April 7, 2015
Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trialJosefina B Cadorna-Carlos, Terry Nolan, Charissa Fay Borja-Tabora, et al.
Annals of the Rheumatic Diseases|November 5, 2020
Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritisRoy M Fleischmann, Ricardo Blanco, Stephen Hall, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 10, 2020
Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo-Controlled Phase III StudyAtul Deodhar, Ricardo Blanco, Eva Dokoupilová, et al.
Annals of the Rheumatic Diseases|March 6, 2014
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitorArthur Kavanaugh, Philip J Mease, Juan J Gomez-Reino, et al.
Pageof 16